Navigation Links
Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
Date:4/16/2008

VALENCIA, Calif., April 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that Matthew J. Pfeffer will join the company as Corporate Vice President and Chief Financial Officer, effective April 21, 2008. Mr. Pfeffer will report to Hakan Edstrom, President and Chief Operating Officer, and will serve on MannKind's executive leadership team. Mr. Pfeffer's appointment follows the previously announced retirement of Dick Anderson, who has now transitioned to the role of Corporate Vice President -- Office of the Chairman.

Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008, with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine-year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer is a member of the board of directors of Genelabs Technologies, Inc. He also serves on boards and advisory committees of Financial Executives International, the Biotechnology Industry Organization and the American Institute of Certified Public Accountants. Mr. Pfeffer graduated from the University of California, Berkeley and is a Certified Public Accountant.

"Matt is a seasoned and knowledgeable Chief Financial Officer with over 25 years of demonstrated financial management experience. We know that he will play a significant role on MannKind's executive leadership team as we continue to develop our pipeline of diabetes and oncology products," said Hakan Edstrom. "We are extremely pleased to have him on the team."

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
2. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
3. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
4. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
5. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
6. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
7. Cord Blood America Says Pennsylvania Joins New York and California in Establishing Educational Programs on the Benefits of Umbilical Cord Blood Storage
8. Holly Smith Joins Profect as Director of Clinical Imaging Services
9. Ex-Allergan Vice President Joins Kalologie Skincare Board of Directors
10. Dr. Linda McAllister Joins Arbor Vita Corporation as Vice President of Diagnostics
11. Louis Drapeau Joins Bionovos Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):